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Questionnaire; completed by participants ages 40 – 80. After exclusion of persons 
with negative sample weights and missing data, the final sample was 3437. Chi-
square and ANOVA were used to make statistical comparisons and all analyses 
were weighted to account for the sampling design. Results: The prevalence of 
taste dysfunction was 5.3% (95% CI 4.6, 6.1). Taste dysfunction was higher in older 
adults compared to younger adults (6.9% and 4.2%, respectively, p < .01), and in 
those reporting problems with smell compared to those with no problem (21.2% and 
3.4%, respectively, p < .0001). Persons with taste dysfunction reported significantly 
more days of poor physical health (mean = 6.4, SE = 1.1) and mental health (mean 
= 6.2, SE = 1.1) than those without problems with taste mean = 3.9, SE = .24, p = .04; 
mean = 3.7, SE = 0.24, p = .03, respectively). ConClusions: Based on self-reported 
data, taste dysfunction affects 5% of the weighted sample. Discrepancies between 
reported prevalence from 1994 are likely due to differences in the operationaliza-
tion of taste dysfunction. The association of problems with taste and the increase 
in reported days of poor physical and mental health should be investigated further.
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objeCtives: Drugs with anticholinergic properties are associated with central and 
peripheral adverse effects in the elderly. The purpose of this study was to deter-
mine the prevalence and predictors of inappropriate anticholinergic medication 
use among the elderly as per 2012 American Geriatrics Society (AGS) Beers’ crite-
ria. Methods: A retrospective cross-sectional study design was conducted using 
2009-2010 Medical Expenditure Panel Survey (MEPS). The study sample included 
individuals aged ≥ 65 years. Inappropriate anticholinergic drugs were identified 
using the MEPS prescription files. Weighted descriptive statistics were used to esti-
mate the prevalence of inappropriate anticholinergic medication use in elderly 
patients. Multivariable logistic regression within the conceptual framework of 
Anderson Behavioral Model was used to identify predictors associated with the 
use of inappropriate anticholinergic medications in the elderly. Results: Analysis 
of the 2009-2010 MEPS data revealed that an estimated 78.6 million members of 
the US population were elderly. (12.78%) It was estimated that 7.51 million (95% CI: 
6.64 to 8.38) of elderly individuals used potentially inappropriate anticholinergic 
medications, resulting in an overall prevalence of 9.56%. The most frequently used 
inappropriate anticholinergics were cyclobenzaprine (2.08%), promethazine (1.75%), 
amitriptyline (1.47%), hydroxyzine (0.95%), and dicyclomine (0.84%). Multivariable 
analyses revealed that female gender (OR: 1.37; 95% CI: 1.06-1.77), South region (OR: 
1.88; 95% CI: 1.25-2.84) and anxiety disorder (OR: 2.15; 95% CI: 1.57-2.94) increased 
the likelihood of receiving inappropriate anticholinergic medications; whereas age 
between 75 to 84 years (OR: 0.64; 95% CI: 0.49-0.85), age > = 85 years (OR: 0.52; 95% 
CI: 0.33-0.81) and > 15 years of education (OR: 0.54; 95% CI: 0.35-0.84) decreased the 
likelihood of receiving inappropriate anticholinergic medications. ConClusions: 
The study found that approximately one in ten elderly patients used inappropriate 
anticholinergic medications. Several predisposing and need factors were associ-
ated with the use of inappropriate anticholinergic medications. Efforts are needed 
to improve inappropriate prescribing practices to optimize medication use in the 
elderly.
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objeCtives: Health care risk epidemiology identifies medication error as the 
commonest cause of adverse effects on patients. Errors can occur at any phase of 
the medication process, so incidence rates should be estimated along with their 
clinical outcomes at each stage. The aim of this study was to assess and analyze 
the medication errors for determining their nature, types, incidence and clinical 
significance in an Indian setting. Methods: This prospective observational study 
was conducted in 3 medical wards of a public teaching hospital. All the information 
was collected in a standard data collection form. Medication errors were identified 
and analyzed from patients’ records using Current Index of Medical Sciences (CIMS) 
and Micromedex Drug-Reax database. Results: Of the 450 studied, 87 patients 
were found to have 113 medication errors. The 3 most common errors were drug 
interactions followed by inappropriate frequency and overdose (35%, 23% and 8%, 
respectively). Other errors were underdose, incomplete prescription and duplication 
of therapy. Nitrofurantoin, domperidone & cefixime were common drugs admin-
istered at inappropriate frequency. Drugs involved in overdose were enoxaparin, 
gentamicin, azithromycin & domperidone. The incidence of medication error was 
26%. Antimicrobial agents (34%) had contributed maximum to the error followed 
by GI agents (20%), anticoagulants (11%) and CNS agents (8%). All the errors were 
category B error (NCC MERP medication error index) ConClusions: The avail-
ability of such evidence will help in improving patient safety in Indian setting and 
to promote medication safety.
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objeCtives: Causality assessment is the evaluation of the likelihood that a particu-
lar treatment is the cause of an observed adverse event. The aim of this study was to 
ication, which increased to 53.2% by 5 years. Overall, ADHD drug use was most com-
mon in patients aged 1-5 and 6-12 years whereas antipsychotics were most common 
in adolescents (13-17 years) and young adults (18-25 years). The effects of age group 
on the use of the different drug classes were statistically significant (p< 0.0001). We 
observed significant changes in drug use over time for all psychoactive drug classes 
(either increase or decrease), except for anxiolytics. ConClusions: Psychoactive 
medication use increased over the 5-year period among newly diagnosed ASD peo-
ple, whatever the age group. Optimal use of these medications in the context of 
limited access to other types of support modalities is discussed.
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objeCtives: The objective of this study was to determine if long-acting reversible 
contraception (LARC) use prior to pregnancy and health plan type were associated 
with greater likelihood of having an intended pregnancy (IP). Methods: Women 
members of the Kaiser Permanente, Northern California (KPNC) integrated health 
plan aged 15-44 years who became pregnant between 1/1/2010 and 12/31/2012 were 
identified from KPNC databases. The last contraceptive method used within 2 years 
preceding pregnancy was determined. Key characteristics were compared among 
women with IPs vs. those with unintended pregnancies (UPs-unwanted or mis-
timed). Logistic regression analyses were conducted to determine if health plan 
type, copays or prior LARC use were predictive of IP, controlling for age, race/ethnic-
ity, marital status, education/income, parity, and select comorbidities. Results: 
Among women included in the study, 27,498 (61%) had IPs and 17,853 (39%) had 
UPs. Higher education (47.9% vs. 17.2%), an income ≥ $60,000 (55.0% vs. 21.0%), 
and already having one child (39.0% vs. 21.3%) were significantly (p< 0.0001) more 
common among women with IPs. In comparison to women with IPs, significantly 
(p< 0.0001) larger proportions of women with UPs were ≤ 24 years old (33.7% vs. 
6.5%), single (39.8% vs. 5.5%), and had evidence of comorbidities (7.72% vs. 7.12%). 
When controlling for key characteristics, women who used LARC methods prior to 
pregnancy vs. women using non-LARC methods were 2.3-fold (p< 0.0001) more likely 
to have an IP. Women with deductible plans with health savings accounts (HSA) vs. 
those with non-deductible plans had greater odds of having an IP (1.16, p= 0.01). 
Upon further stratified analysis, prior use of LARC methods was associated with 
significantly greater likelihoods of having an IP across all evaluated race/ethnicities 
and education/incomes levels. ConClusions: Women KPNC members who used 
LARC methods prior to pregnancy and those who had a HSA were more likely to 
have an IP than an UP.
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aUtIsM Prevalence In cHIldren aMong tHe UnIted states MedIcaId 
PoPUlatIon
Xie L.1, Dysinger A.H.1, Wang L.2, Zhang J.2, Shrestha S.2, Wang Y.1, Baser O.3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA, 
3STATinMED Research and The University of Michigan, Ann Arbor, MI, USA
objeCtives: The current study examined patient age, gender, race, geographic 
variation as well as the prevalence of autism in children using U.S. Medicaid 
data. Methods: A retrospective study was performed among the Medicaid fee-for-
service (FFS) population from January 1, 2008 through December 31, 2009. Children 
under age 17 years and diagnosed with autism were identified using International 
Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis 
code 299.0x. A 2-year period of continuous Medicaid FFS enrollment during the 
study period was required. Disease prevalence was stratified by region, state, age, 
gender and race for all patients, and measured by number and percentage in each 
category. Patients with managed care enrollment in any month of 2008 or 2009 
were excluded from the study. Results: A total of 23,589 children diagnosed with 
autism were analyzed. Children age 6-10 years had the highest autism prevalence 
level (4.59%), followed by those age 11-17 (3.62%) and 0-5 years (1.50%). Prevalence 
results according to race are as follows: Asian (6.33%), White (4.06%), Hispanic (3.29%) 
and Black (2.75%). Autism was more likely to be diagnosed among boys (5.01%) than 
girls (1.62%). Geographic variation analysis showed the highest autism prevalence 
in Idaho (34.06%), followed by Oklahoma (17.14%), Connecticut (14.05%), Minnesota 
(13.44%) and Rhode Island (11.33%). The Southern region of the United States was 
found to have the highest autism prevalence for children under age 17 (4.35%), com-
pared to the Midwest (4.03%), Northeast (3.43%) and West (0.82%). ConClusions: 
Children age 6-10 years had a higher probability of being diagnosed with autism, 
with Asian patients most likely to be diagnosed with autism compared to other 
races. Children residing in the Midwestern region of the United States were shown 
to be at a higher risk for an autism diagnosis.
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objeCtives: There are no current nationally representative estimates on taste 
dysfunction for the US population; the last estimates based on the 1994 National 
Health Interview Study indicated population prevalence reports of taste problems 
of 0.6%. The purpose of this study is to provide current estimates of the preva-
lence of taste dysfunction and identify the relationship between taste dysfunction 
and health perception in the US population. Methods: Data from the 2011-2012 
National Health and Nutrition Examination Survey (NHANES) was used to assess 
the prevalence of self-reported taste dysfunction as assessed by the Taste and Smell 
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objeCtives: Abnormal uterine bleeding (AUB) interferes with physical, emotional, 
and social well-being, impacting the quality of life of more than 10 million women in 
the US. Hysterectomy, the most common surgical treatment of AUB, has significant 
morbidity, low mortality, long recovery, and high associated health care costs. Global 
endometrial ablation (GEA) provides a surgical alternative with reduced morbid-
ity, cost, and recovery time. The NovaSure system utilizes unique radiofrequency 
impedance-based GEA technology. This study evaluated cost-effectiveness of AUB 
treatment with NovaSure ablation versus other GEA modalities and versus hys-
terectomy from US commercial and Medicaid payer perspectives. Methods: A 
health state transition (semi-Markov) model was developed using epidemiologic, 
clinical, and economic data from commercial and Medicaid claims database analy-
ses, supplemented by published literature. Three hypothetical cohorts of women 
receiving AUB interventions were simulated over 1-, 3-, and 5-year horizons to 
evaluate clinical and economic outcomes for NovaSure, other GEA modalities, and 
hysterectomy. Results: Model analyses show lower costs for NovaSure-treated 
patients than for those treated with other GEA modalities or hysterectomy over 
all timeframes under commercial payer and Medicaid perspectives. By Year 3, cost 
savings versus other GEA were $930 (commercial) and $3,000 (Medicaid); cost savings 
versus hysterectomy were $6,500 (commercial) and $8,900 (Medicaid). Coinciding 
with a 43%-71% reduction in need for re-ablation, there were 69%-88% fewer inter-
vention/reintervention complications for NovaSure-treated patients versus other 
GEA modalities, and 82%-91% fewer versus hysterectomy. Furthermore, NovaSure-
treated patients had fewer days of work absence and short-term disability. Cost-
effectiveness metrics showed NovaSure treatment as economically dominant over 
other GEA modalities in all circumstances. With few exceptions, similar results were 
shown for NovaSure treatment versus hysterectomy. ConClusions: Model results 
demonstrate strong financial favor for NovaSure ablation versus other GEA modali-
ties and hysterectomy from commercial and Medicaid payer perspectives. Results 
will interest clinicians, health care payers, and self-insured employers striving for 
cost-effective AUB treatments.
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lIfetIMe HealtH and econoMIc conseqUences of obesIty-related 
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MedIcal exPendItUre Panel sUrvey
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objeCtives: This study analyzed lifetime health and economic consequences of 
multiple obesity-related diseases (ORDs), including diabetes, hypertension, coro-
nary heart disease (CHD), and stroke. Methods: Nationally representative data 
of the U.S. civilian, non-institutionalized population was used. Our sample was 
from the National Health Interview Survey (NHIS), 1997-2000, and linked to the 
NHIS Linked Mortality Public-Use Files to estimate mortality risks. The sample was 
further linked to the Medical Expenditure Panel Survey (MEPS) to estimate annual 
health care expenditures. Disease risks were estimated with National Health and 
Nutrition Examination Survey (NHANES) data. Analyses were stratified by gender 
and adjusted for age, race, and BMI groups. Complex sampling designs in NHIS, 
MEPS, and NHANES were adjusted for. A Markov model populated by estimates 
of disease and mortality risks and health care expenditures was built to compute 
life years and lifetime health care expenditures for gender-race-age-BMI-specific 
subpopulations. Results: Our sample comprised of 17,917 women and 13,928 men. 
For individuals age 40, life years lost associated with ORDs for women ranged from 
2.7 (obese, not white or black, with CHD) to 14.6 (normal-weight, white, with all 
four ORDs) and for men from 2.3 (obese, not white or black, with diabetes) to 12.4 
(normal-weight, not white or black, with all four ORDs). Lifetime health care expend-
iture increment associated with ORDs for women ranged from $27,749 (normal-
weight, white, with hypertension) to $277,949 (overweight, not white or black, with 
all four ORDs) and for men from $41,804 (normal-weight, black, with hypertension) 
to $249,829 (overweight, not white or black, with all four ORDs). ConClusions: This 
study suggests that the lifetime health and economic consequences associated with 
ORDs are higher for women than men. And disease burden increases with increas-
ing number of ORDs. Diabetes is the most costly ORD. Among sets of two ORDs, the 
combination of diabetes and hypertension is the most costly.
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PeyronIe’s dIsease In tHe UnIted states
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objeCtives: Compare health care costs and resource utilization between patients 
with Peyronie’s disease (PD) and matched controls without PD. Methods: Male 
adults aged ≥ 65 in Medicare Advantage plans or aged 18-64 in commercial plans 
with ≥ 1 PD diagnosis (ICD-9-CM: 607.85) between 1/1/2007-12/31/2012 were selected 
from a national claims database comprised of 14M enrollees. The index date was 
defined as the observed first date with a PD diagnosis. Continuous eligibility for ≥ 6 
months before (baseline period) and 1 year after (study period) the index date was 
required. PD patients (cases) were matched on age, gender, race, geographic region, 
plan type, index year, baseline health care costs and comorbidities to patients with-
out PD, Dupuytren’s contracture, or Ledderhose disease diagnoses in their claims 
histories (controls) by propensity score matching. Descriptive analyses compared 
baseline characteristics and post-index resource utilization between cohorts. As 
indicated by Box-Cox test and Park test, generalized linear models with gamma 
distribution and log link were used to compare risk-adjusted health care costs 
inflated to $2013 US dollars. Results: 1,528 Medicare PD patients (mean age 70 
years) and 768 commercial patients (mean age 51 years) met the inclusion criteria. 
PD patients had significantly higher comorbidities compared with their controls 
(e.g., erectile dysfunction (ED), other male genital organs diseases, urinary diseases, 
diabetes and hyperlipidemia) (all p< .05). During the study period, PD patients had 
compare the different methods adopted for the detection of the ADRs. Methods: 
A prospective observational study was carried out at the three general wards of 
medicine department of an Indian public teaching hospital. The three different 
scales for causality assessment used were Naranjo‘s ADR probability scale, WHO-
UMC causality category and, Karch and Lasagna scale. Results: Only 60 ADRs were 
identified in 520 patients studied. All the identified ADRs were assessed for causality 
using different causality assessment scales. According to Naranjo‘s ADR probability 
scale, 52 of the reactions were ‘probable’, 8 of the reactions were ‘possible. 28 ADRs 
were ‘probable’ and 32 were ‘possible’, according to WHO-UMC causality category. 
According to Karch and Lasagna scale, 45 ADRs were ‘probable’ and 15 were ‘pos-
sible’. A comparison between three scales showed that there is a closer match in 
the ‘probable’ ADRs between Naranjo and Karch & Lasgna scales (87% & 75%), 45% 
ADRs were probable (WHO-UMC method). Out of these three methods WHO-UMC 
method was found to be simple to use. ConClusions: Causality assessment helps 
to assess the link between the drug and the ADRs. There is a disagreement between 
the outcomes of the study when three methods were used for causality assessment 
of reported ADRs.
IndIvIdUal’s HealtH – cost studies
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bUdget IMPact of UtIlIzIng varIoUs tyPes of advanced bIPolar 
energy (abe) devIces versUs conventIonal bIPolar energy (cbe) In 
total laParoscoPIc HysterectoMy In canadIan HosPItals
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objeCtives: Electrosurgical instruments have proven to be effective at achieving 
hemostasis in laparoscopic hysterectomy and in Canada, their usage is increas-
ing. ABE devices have several advantages over conventional bipolar energy (CBE) 
including decreased thermal damage to tissue, improved ease-of-use and greater 
physician control. While all ABE devices have advantages over CBE technology, each 
of the 3 available ABE systems impact procedure time and length of stay differ-
ently. One disadvantage of all 3 ABE systems is the premium pricing as compared 
to CBE. This study was conducted to determine the budget impact of switching 
from CBE to 3 different ABE systems for benign laparoscopic hysterectomies in 
Canadian hospitals. Methods: The budget impact model considers the inpatient 
and procedural costs incurred by a Canadian hospital performing 100 procedures 
annually. CBE is utilized as a baseline for efficacy and each of the 3 ABE systems 
are compared to CBE individually. Data on the use of health care resources was 
obtained from published prospective randomized/non-randomized controlled trials. 
Additional costing data was obtained from the Ontario Case Costing Initiative and 
a large Canadian hospital. The device costs were collected from market research. 
A multivariate sensitivity analysis using a Monte Carlo simulation was completed 
to ensure scientific rigour. Results: When comparing the 3 forms of ABE to CBE, 
EnSeal was the only technology that significantly reduced both OR time and length 
of stay. This reduction in health care resources offsets Enseal’s premium price result-
ing in an equivalent budget impact to CBE. However, the other 2 ABE systems do 
not show a reduction in OR time or length of stay and as a result, cost a Canadian 
hospital on average $30,239.93 and $93,091.44 more than CB or EnSeal per annum 
for laparoscopic hysterectomies. ConClusions: EnSeal is as cost-effective as CBE 
for benign laparoscopic hysterectomies in a Canadian hospital.
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cost analysIs of tHe robotIc sUrgery In Italy
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objeCtives: The purpose of the study is to determine the cost of robotic surgery in 
comparison with traditional surgery, both in the NHS and societal perspective, in 
the Italian setting. Methods: The prospective multicentre study performed a cost 
analysis on about 700 patients enrolled for the period February 2011 - December 2013 
in 8 Italian Hospitals. The interventions were general, thoracic and gynaecological 
surgery performed with open, laparoscopic or robotic technique. The model was 
developed considering both direct and indirect costs in the various phases of the 
intervention: patients enrollment and hospitalization, first follow up one month 
after discharge, next follow up. The model used tariffs for direct health care costs 
as laboratory, instrumental tests and specialist visits. For all other health care direct 
costs, non health care direct costs and indirect costs the model used real costs and 
resources data. Results: In NHS perspective all specialties of robotic and open 
interventions cost 9,471€ vs 7,232€ , p< 0.01. Indirect costs are lower in robotics ver-
sus open: 928€ vs 872€ , p< 0.05; this could be explained by lower length of stay of 
robotic vs open (7.78 days versus 6.41, p< 0.01). In the societal perspective, costs for 
all specialties (robotics: 10,909€ ; open: 8,681€ ; laparoscopic: 8,303€ ), show differ-
ences between robotic and traditional surgery, as open and laparoscopic interven-
tions present the same level of total costs. ConClusions: Robotic surgery is more 
expensive than traditional techniques, the operating times decrease with increasing 
experience of the surgeon in the use of the robot. It is important to highlight the 
benefits of the use of the robot in terms of ease of execution of complex interven-
tions by both surgeon and experienced assistant. This should also have a positive 
impact on the quality of life of patients who should receive a level of postoperative 
pain in the lower robotic interventions.
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